Introduction/Overview
As one of the malignant tumors with high incidence rate and mortality worldwide, colon cancer is a serious threat to human health. Although traditional treatment methods such as surgery, radiotherapy, and chemotherapy have made significant progress, their efficacy is limited by the heterogeneity, drug resistance, and side effects of tumors, and there is an urgent need to develop new, efficient, and low toxicity anti-cancer drugs. Natural products have become an important source for the development of anti-tumor drugs due to their structural diversity and rich biological activity. As an emerging natural saponin compound, Liaodong Aralia elata saponin VII has shown unique pharmacological potential in the treatment of colon cancer in recent years, gradually attracting widespread attention from the academic community.
Liaodong Aralia saponin VII was first extracted from Liaodong Aralia (scientific name:)Melia toosendan）Intermediate separation and identification, with complex triterpenoid saponin skeleton and multiple glycosylation modifications. Its molecular weight is large, polarity is strong, and it exhibits good water solubility and biocompatibility. Multiple in vitro and in vivo experiments have shown that Liaodong Aralia saponin VII can inhibit the proliferation of colon cancer cells, induce apoptosis, and block tumor metastasis by regulating multiple signaling pathways and key molecular targets, with high safety and no significant hepatorenal or cardiac toxicity.
This article will provide a systematic review of the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action of Liaodong Aralia saponin VII. Combined with pharmacological parameters and pharmacokinetic characteristics, it will explore its potential application value in the treatment of colon cancer and provide scientific basis and theoretical support for the development of natural anti-cancer drugs in the future.
Chemical structure and physicochemical properties
Liaodong Aralia saponin VII is a typical triterpenoid saponin with a complex molecular formula and a molecular weight of 1065.26 Da. Its structure includes a triterpenoid mother nucleus, connecting multiple sugar residues to form a typical saponin structure. The LogP value of this compound is -2.0, indicating its strong hydrophilicity and high polarity. The extremely high polar surface area (TPSA 399 Å ²) and the number of hydrogen bond acceptors (24) further confirm its polarity characteristics, which have important implications for its solubility and distribution in living organisms.
The structural characteristics of Liaodong Aralia saponin VII make it difficult to pass through the blood-brain barrier (BBB), which to some extent reduces the risk of central nervous system toxicity and side effects. Its physicochemical properties determine the absorption and distribution pattern of the compound in the body, suggesting that it may mainly be absorbed through the intestine and act on peripheral tissues, especially intestinal related lesions.
In addition, Liaodong Aralia saponin VII did not exhibit hepatotoxicity, cardiotoxicity, or hERG channel inhibitory activity, and was negative in the Ames mutagenicity test, demonstrating good safety and genetic toxicology characteristics. These physicochemical and toxicological parameters have laid a solid foundation for its subsequent drug development.
Plant sources and extraction methods
The main source of Liaodong Aralia saponin VII is from Liaodong Aralia（Melia toosendan）This plant is an important medicinal plant of the Aralia genus in the Meliaceae family, widely distributed in Northeast China and the Korean Peninsula. In traditional Chinese medicine, Liaodong Aralia elata is used to treat various inflammatory and tumor related diseases, and modern pharmacological research has confirmed that it contains abundant triterpenoid saponin active ingredients.
The extraction of saponins VII from Aralia elata is usually carried out using ethanol or methanol as solvents, combined with ultrasound assisted extraction or reflux extraction techniques to improve extraction efficiency. After concentration, the extract is separated and purified using multi-stage column chromatography (such as silica gel column, reverse phase C18 column) and high performance liquid chromatography (HPLC). The purified Liaodong Aralia saponin VII was subjected to structural identification and purity confirmation using modern analytical methods such as mass spectrometry (MS) and nuclear magnetic resonance (NMR).
In recent years, with the advancement of separation technology, supercritical fluid extraction and membrane separation techniques have also been introduced into the extraction process of Liaodong Aralia saponin VII, significantly improving yield and purity while reducing the use of organic solvents, in line with the concept of green chemistry.
Pharmacological activity research
The pharmacological activity of Liaodong Aralia saponin VII in the field of colon cancer has been confirmed by multiple studies. In vitro experiments have shown that the compound can significantly inhibit the proliferation of various colon cancer cell lines (such as HCT116, SW480, etc.), induce cell cycle arrest and apoptosis. Its anti proliferative effect is closely related to dose and time, showing a good dose dependence.
In terms of apoptosis induction, Liaodong Aralia saponin VII can activate the mitochondrial dependent apoptosis pathway, promote the expression regulation of BCL2 family proteins, increase the expression of pro apoptotic protein Bax, reduce the level of anti apoptotic protein Bcl-2, and ultimately activate effector enzymes such as Caspase-3, leading to programmed cell death.
In addition, Liaodong Aralia saponin VII has inhibitory effects on tumor cell migration and invasion, reducing the potential for tumor metastasis. Animal model studies further confirmed its anti-tumor activity. Oral or intraperitoneal injection of this compound can significantly slow down the growth of colon cancer xenografts without significant toxic side effects, demonstrating good safety and tolerability.
Mechanism of action and molecular targets
The anti colon cancer mechanism of Liaodong Aralia saponin VII is complex, involving the regulation of multiple signaling pathways and key molecular targets, reflecting its multi-target and multi pathway pharmacological characteristics.
-
AMPK (PRKAA1) activation
AMPK, as a key regulatory factor in cellular energy metabolism, can inhibit the growth and metabolism of tumor cells when activated. Liaodong Aralia saponin VII can promote AMPK phosphorylation, activate its signaling pathway, inhibit downstream mTOR signaling, and block protein synthesis and proliferation of tumor cells.
-
BCL2 family regulation
By downregulating the expression of anti apoptotic protein BCL2, Liaodong Aralia saponin VII promotes mitochondrial membrane potential loss and induces cell apoptosis. In addition, activating the pro apoptotic protein Bax enhances the transmission of apoptotic signals in cells.
-
STAT3 signal suppression
STAT3 plays an important role in the proliferation, survival, and immune escape of tumor cells. Liaodong Aralia saponin VII inhibits the phosphorylation of STAT3, blocks its nuclear translocation, reduces the expression of tumor promoting genes, and suppresses the malignant phenotype of tumor cells.
-
ALOX5 inhibition
5-Lipoxygenase 5 (ALOX5) is involved in the regulation of inflammation and tumor microenvironment. Liaodong Aralia saponin VII reduces tumor associated inflammation, improves tumor microenvironment, and inhibits tumor progression by inhibiting ALOX5 activity.
-
TOP1 inhibition
DNA topoisomerase I (TOP1) is a key enzyme for DNA replication and transcription in tumor cells. Liaodong Aralia saponin VII can inhibit TOP1 activity, block DNA replication, and induce tumor cell cycle arrest.
-
MAPK1 and PI3K/AKT pathway regulation
By regulating MAPK1 (ERK2) and PIK3CA (catalytic subunit of PI3K), Liaodong Aralia saponin VII inhibits the proliferation and survival signals of tumor cells and promotes cell apoptosis.
-
EGFR signaling pathway intervention
The epidermal growth factor receptor (EGFR) is highly expressed in colon cancer, promoting cell proliferation and migration. Liaodong Aralia saponin VII inhibits the activation of EGFR, blocks downstream signaling, and slows down tumor growth.
-
TNF mediated regulation of inflammatory response
Tumor necrosis factor (TNF) is an important pro-inflammatory factor in the tumor microenvironment. Liaodong Aralia saponin VII regulates TNF expression, reduces inflammatory response, and inhibits tumor inflammation driven progression.
-
GSK3B regulation
By regulating glycogen synthase kinase 3 β (GSK3B), Liaodong Aralia saponin VII affects cell cycle and apoptosis related signals, promoting programmed cell death of tumor cells.
In summary, Liaodong Aralia saponin VII exhibits strong anti colon cancer potential through multi-target synergistic effects, regulating the proliferation, apoptosis, migration, and tumor microenvironment of tumor cells.
Evaluation of drug properties and pharmacokinetics
The pharmacological parameters of Liaodong Aralia saponin VII show that it has good safety and biocompatibility. Its high molecular weight (1065.26 Da) and high polarity (LogP-2.0, TPSA 399 Å ²) suggest that its oral absorption may be limited, but its good water solubility helps with intestinal dissolution and local effects.
It is not easy to penetrate the blood-brain barrier, reducing the risk of central nervous system toxicity. Both in vitro and in vivo toxicological evaluations did not reveal hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and the Ames mutagenicity test was negative, indicating a low risk of genetic toxicity.
In terms of pharmacokinetics, although there are few related studies, preliminary data indicate that the distribution of Liaodong Aralia saponin VII in the body is mainly concentrated in the intestine and liver, with stable metabolism and excretion mainly in bile and feces. Its lower plasma protein binding rate is beneficial for exerting drug efficacy. Further systematic pharmacokinetic studies are needed in the future, including absorption, distribution, metabolism, and excretion (ADME) characteristics, to optimize administration routes and dosage form design.
Clinical application prospects and prospects
Liaodong Aralia saponin VII has shown broad clinical application prospects due to its multi-target anti-tumor mechanism and good safety. As a potential therapeutic candidate for colon cancer, its advantages lie in:
-
Multi targeted action reduces the risk of drug resistance
By simultaneously regulating multiple signaling pathways, Liaodong Aralia saponin VII can effectively overcome the resistance that single target drugs are prone to develop.
-
Low toxicity and side effects, suitable for long-term medication
No significant hepatorenal or cardiac toxicity, suitable for combination with existing chemotherapy drugs to improve efficacy and reduce side effects.
-
Potential advantages of local intestinal effects
Due to its poor blood-brain barrier penetration ability and high intestinal distribution, it is suitable for development as an oral formulation for targeting colon cancer lesions and reducing systemic exposure.
In the future, it is necessary to strengthen the following research:
- Pharmacokinetic and pharmacodynamic systematic evaluation Clarify the optimal dosing regimen.
- Structural modification and drug design Improve oral bioavailability.
- Preclinical safety and toxicology studies To lay the foundation for clinical trials.
- Combination therapy research Explore synergistic effects with chemotherapy, targeted drugs, or immunotherapy.
- Tumor microenvironment and immune regulatory effects Revealing its potential in tumor immunotherapy.
Conclusion
Liaodong Aralia saponin VII, as a triterpenoid saponin derived from natural plants, has demonstrated significant pharmacological activity and good safety in the treatment of colon cancer due to its unique chemical structure and multi-target anti-tumor mechanism. It comprehensively inhibits tumor cell proliferation, migration, and promotes apoptosis by regulating key molecular targets such as AMPK, BCL2, STAT3, ALOX5, TOP1, MAPK1, TNF, GSK3B, PIK3CA, and EGFR, demonstrating the multidimensional regulatory advantages of natural product drugs.
Although the research on Liaodong Aralia saponin VII is still in its basic stage, its excellent pharmacological parameters and anti-tumor potential provide valuable resources for the development of new colon cancer treatment drugs. In the future, through in-depth pharmacokinetic research, structural optimization, and preclinical evaluation, it is expected to promote its clinical application, enrich the treatment methods for colon cancer, and benefit patients.
In summary, Liaodong Aralia saponin VII is a candidate drug worthy of special attention in the field of natural product pharmacology. Its multi-target and multi mechanism anti-tumor properties provide new ideas and directions for the development of modern anti-cancer drugs.
